Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.
| Revenue (TTM) | $5.32B |
| Gross Profit (TTM) | $3.27B |
| EBITDA | $816.00M |
| Operating Margin | 7.75% |
| Return on Equity | -2.52% |
| Return on Assets | 1.83% |
| Revenue/Share (TTM) | $14.99 |
| Book Value | $18.09 |
| Price-to-Book | 0.95 |
| Price-to-Sales (TTM) | 1.14 |
| EV/Revenue | 2.028 |
| EV/EBITDA | 14.69 |
| Quarterly Earnings Growth (YoY) | -88.60% |
| Quarterly Revenue Growth (YoY) | 9.10% |
| Shares Outstanding | $357.17M |
| Float | $45.23M |
| % Insiders | 87.32% |
| % Institutions | 11.70% |
Volatility is currently contracting
LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb Corporation (NYSE: BLCO)(TSX: BLCO), a subsidiary of Bausch Health Companies Inc., effective August 5, 2026.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the c.
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb NYSE: BLCO reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook. The company said improved product mix, productivity initiatives and lower fixed-cost intensity supported margin expansion and stronger cash generation.
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.07 per share a year ago.
BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has dec.
VAUGHAN, Ontario, & MENLO PARK, Calif.--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the creation of Orphia™, a new AI-powered digital health platform built on the belief that eye care providers should spend less time managing disconnected tools and technologies and more time caring for patients. The platform is brand agnostic and designed to serve all eye care providers, r.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year's survey was conducted online by The Harris Poll in May 2026 among 1,000 dry eye suff.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BLCO and any ticker you trade — then tracks every position and per-strategy win rate.
